<DOC>
	<DOCNO>NCT01183169</DOCNO>
	<brief_summary>The study investigate whether participant hepatitis C virus ( HCV ) genotype 1 history non-response/relapse peginterferon alfa-2a ( PEG ) ribavirin ( RBV ) may benefit treatment triple therapy alisporivir ( ALV ; DEB025 ) PEG RBV versus placebo PEG RBV .</brief_summary>
	<brief_title>Efficacy Safety Adding Alisporivir ( DEB025 ) Peginterferon ( IFN ) Alfa-2a ( Peg-IFN Alfa-2a ) Ribavirin Chronic HCV Genotype 1 Patients Who Relapsed Did Not Respond Previous Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Inclusion criterion : Chronic HCV genotype 1 viral infection HCV RNA â‰¥ 1,000 IU/ml assess quantitative polymerase chain reaction ( qPCR ) equivalent screen Previous nonresponders/relapsers PEG RBV treatment least 12 week Exclusion criterion : Treatment antiHCV drug ( whether approve investigational ) within 3 month prior screen Women childbearing potential unless use highly effective Any cause relevant liver disease HCV Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Cyclophilin inhibitor</keyword>
</DOC>